Lung cancer is the main cause of cancer deaths for both men and women in the US and worldwide. 
certain subgroups of lung cancer patients. 6, 7 However, less is known about how to translate underlying mechanisms governing the protumor role of the immune system into meaningful clinical tools.
Over a lifetime, the lungs are constantly exposed to an array of toxic environmental particles that can potentially result in chronic inflammatory responses with life-altering consequences, which is particularly important for tobacco smokers, whose airways are exposed to the carcinogenic agents present in cigarettes. The link between the immune system and cancer is not new, and dates back as far as 1550BCE. 8 In the1890s, William Coley, a surgeon in New York, was one of the modern pioneers linking cancer to the immune system. He described how a recurrent facial sarcoma successfully regressed after concurrent infection with erysipelas. 9 Unfortunately, his rather innovative hypothesis was not solidly supported by evidence but rather by some anecdotal success, and was met with great skepticism from the medical community. Coley's views were not further explored for many decades, until it was observed that subsequent to solid-organ transplantation immunosuppressed patients were at increased vulnerability for developing skin and some hematological malignancies, such as lymphoma. These observations partly fueled the immune surveillance theory, simplistically implying that failed antitumor adaptive immunity underlies cancer development. 10 More recently, however, fundamental advances in dissecting the nature and bioactivity of leukocytes in lung cancers and other solid tumors indicate that activation of pro-tumor immune response programs may negate antitumor immunity aimed at eradicating neoplastic cells. As ~85% of all lung cancers are thought to have a common etiology in tobacco inhalation, and as chronic inflammatory responses are known to result from this exposure, it seems reasonable to consider novel therapeutic strategies aimed at neutralizing the pro-tumor properties of chronic inflammation while simultaneously bolstering antitumor programs to more effectively eliminate and/or arrest malignant cells. These, together with enhanced national and global strategies to educate people regarding the health risks of smoking and funding of smoking prevention/cessation programs, should be encouraged. 11 Thus, in this article we discuss the relevant literature illuminating the role of the immune system in the respiratory tract critical for maintaining physiological homeostasis, as opposed to the role the immune system plays during development of lung cancer. These studies are then used as a backdrop to explore recent advances in immunotherapy of lung cancer and the clinical trials assessing vaccine-based therapies and their delivery in lung cancers.
The Immunology Behind Cancer Vaccines
The immune system in mammals is composed of various cell types and mediators that interplay in a complex manner with each other and nonimmune cells in dynamic yet complex networks ensuring the defense against pathogens, while simultaneously maintaining tolerance towards self-antigens. Based on antigen specificity and chronology of activation, 
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The lungs are functionally divided into two distinct tissue compartments: the conducting airways, covered by the mucosa, and the pulmonary parenchyma, containing thin-walled alveoli involved in gas exchange (see Figure 1 ). These compartments, with contrasting levels of 
Induction of Cellular Immunity in the Lung
Mucosal surfaces of the upper respiratory airways are chronically exposed to a vast number of environmental antigens, most of which are non-pathogenic in nature. Therefore, in order to protect themselves from unnecessary destructive autoimmunity, the default immune modality is a non-inflammatory, low-level Th2-cell immunity and/or a form of T-cell-mediated immunological tolerance, integrin. 61 Moreover, the airway mucosal endothelial cells constitutively express CC-chemokine ligand 28 (CCL28) and vascular cell-adhesion molecule 1 (VCAM1). 61 Respiratory T cells have a different phenotype from gut-homing T cells. 67 In the lung parenchyma, leukocytes migrate through pulmonary capillaries. Research in both murine models and humans has
shown that memory CD8 + T cells specifically target respiratory viruses that accumulate in the lung parenchyma.
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In non-inflammatory conditions, the pulmonary vasculature expresses intercellular adhesion molecule 1 (ICAM1) and P-selectin; however, it does not express VCAM1.
Vascular retention and emergence of effector CD8 + T cells to the normal mouse lung is mediated by the action of lymphocyte function-associated antigen 1 (LFA1)-ICAM1 and CCR5-CCR5-ligand interactions. 69 Furthermore, inhibition of P-selectin glycoprotein ligand 1 (PSGL1)
resulted in the decrease of T cells in both the alveoli and lung parenchyma. 69 Recently, CXC-chemokine receptor 6 (CXCR6) and its ligand were shown to be specifically expressed by human T cells and the lung parenchyma suggesting that they may be involved in tissue-specific lung homing. 70 In conclusion, in physiological conditions the immune system, with the effective and tight regulation of its differing subpopulations of immune cells, exerts a status quo of surveillance that is able to differentiate between potentially harmful pathogenic antigens and the other vast majority of non-harmful environmental antigens to which the lungs are constantly exposed. Thus, damage to the lungs through unnecessary immune responses is limited and local respiratory homeostasis is maintained.
Rationale for Exploiting the Immune System in Lung Cancer
Traditionally, compared with, for example, melanomas, lung cancers were thought not to contain many tumor-infiltrating lymphocytes, which for some time led to lung cancer being thought of as modestly immunogenic. 71 This ethos is changing due to research in animal models and also in human NSCLC specimens demonstrating significant has been used non-specifically for immunotherapy of bladder cancer, 88 is the most widely used immunogenic adjuvant in lung malignancies.
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The individual role of intrapleurally administered BCG in lung cancer has been assessed in several studies with no improvement to survival.
Furthermore, Mycobacterium vaccae (SRL172) with concurrent chemotherapy has been examined as a non-specific immunogenetic adjuvant without success, as shown by a phase III study in NSCLC with no effect on survival. is utilized to isolate monocytes with GM-CSF used to induce differentiation into mature DCs. 105 These are then exposed to specific tumor antigens and subsequently reinoculated into the patient to induce a therapeutic antigen-specific immune response. [106] [107] [108] [109] [110] [111] [112] The effector arms of antitumor immunity are CD4 + and CD8 + cells, which can recognize antigen only when it is presented by APCs. 107, 108 Upon administration, the DCs should migrate to secondary lymphoid organs and induce an antigen-specific immune response.
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We will now describe and discuss aspects of various types of lung cancer vaccines and the clinical trials behind their ethos (see Table 1 ).
Antigen-specific Vaccine Clinical Trials
In order for a tumor antigen to be a suitable target for vaccine therapy, it should be expressed homogeneously in the cancer of interest, should differ from those expressed in nearby normal cells, and should be immunogenic and tumorigenic. Specific tumor-associated antigens such as Wilms' tumor protein (WT1) and some gangliosides, which play a role in cell-cell recognition, cell-matrix adhesion, and cellular differentiation, 113, 114 have been used in the design of lung cancer vaccines. 
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ALVAC is a canarypox vaccine artificially expressing the carcinoembryonic antigen (CEA), which is expressed in many malignancies, including lung cancer, and the co-stimulatory molecule B7. 115 This agent has been tested in a phase I/II study of 18 patients with advanced tumors (three lung cancer patients) bearing CEA;
clinically stable disease was obtained in three patients. 
Dencritic Cell Vaccine Trials
There has been a number of phase I and II trials of DC vaccines that have included some patients with malignant lung lesions, DC vaccines seem to be well-tolerated with biological activity in a heterogeneous group of NSCLC patients. Establishing an optimal approach will require carefully conducted comparative studies in well-defined NSCLC patient groups.
Conclusion and Future Perspectives
The respiratory tract with a surface area of 70m 2 in adults is constantly exposed to the external environment and its associated dwelling particles and pathogens. A single-cell-thick epithelial layer covering the tracheobronco pulmonary respiratory tree allows blood oxygenation throughout life. Therefore, it is obvious that this organ has developed specific tactics over millions of years to maintain homeostasis and prevent the fatality that would ensue upon its failure. Fortunately, recent progress in the understanding of the cellular and molecular events governing this organ during physiology and disease are allowing us to extrapolate and translate knowledge into immunological tools against myriad diseases including lung cancer. There have been many pre-clinical and phase I and II studies evaluating lung cancer vaccines (see Table 1 ), and some phase III trials are under way.
In order to facilitate these studies and ensure that they yield useful information that can be utilized in a meaningful manner in our quest to develop useful vaccines for lung cancer, a few concepts must be taken into consideration. First, adequate patient selection for clinical trials is important. The majority of trials have concentrated on patients with advanced disease. The rationale supporting this is sound because a higher numbers of events in a short period of time permits the study to be powered to demonstrate survival benefit; however, research in animals has not shown a significant reduction in tumor size, 149 which suggests that the optimal candidate for these vaccines is a patient with early-stage disease who has undergone bulky resection but who is at an increased risk for disease recurrence because of microscopic residual disease. This implies better understanding of tumor biology and good biomarkers to identify such individuals (see Figure 2) . Second, disease end-points employed in chemotherapy studies are not necessarily extrapolable to cancer vaccines. 150 Equally, many studies have shown that immune response does not necessarily correlate to clinical response and, therefore, potentially useful markers of immunity may ultimately be useless.
Perhaps it is valid to suggest that the most cost-effective role for cancer vaccines may lie in prevention rather than cure, as is the case in many infectious diseases; however, in cancer the matter of world-renowned in these fields.
